



# Medicaid Pharmacy News

Dear Providers:

September 12, 2019

## **PREFERRED LONG-ACTING NARCOTICS**

Effective September 18, 2019, Embeda, Butrans, and morphine ER tablets will be the preferred long-acting narcotics. Fentanyl patches will be considered non-preferred, however clients that have been stabilized on fentanyl patches will be allowed to continue therapy. Please note that all narcotic limitations, including dosage limits and no concurrent use with a second long-acting narcotic, a benzodiazepine, or a buprenorphine/naloxone product will still be in effect for the preferred agents.

## **MISCELLANEOUS UPDATES**

- Ezallor – will be non-preferred and will require a 90-day trial and failure of a preferred agent within the last year
- Evekeo/ODT and Adhansia XR – will be non-preferred and require a 30-day trial and failure of two preferred agents (one methylphenidate and one amphetamine) within the last year
- Guardian Continuous Blood Glucose Monitor – will be non-preferred
- Sklice – will be non-preferred and will require trial and failure of a preferred agent within the last year
- Letrozole – will require prior authorization and will be limited to approved indications
- Enbrace HR – will require prior authorization and will be limited to a diagnosis of macrocytic anemia associated with pregnancy
- Mirtazapine 7.5mg – will now be preferred
- Solifenacin – will now be preferred, brand name Vesicare will be non-preferred
- Kalydeco Pak – will require justification as to why the client is unable to use tablets
- Mavenclad – will be non-preferred and will require a trial of two preferred agents (each from a separate class)
- Evenity – will be non-preferred and will require a 12-month trial of a preferred agent, will only be allowed for a maximum of 12 months of treatment, will not be allowed with any concurrent osteoporosis treatment, and will be limited to approved indication
- Vyndaqel and Vyndamax – will require prior authorization and will be limited to approved indication
- Diacomit – will require prior authorization, will be limited to approved indication, and will require concurrent use with clobazam
- Zolgensma – will require prior authorization and will be limited to approved indication
- Ruzurgi – will require prior authorization and will be limited to approved indication